8-K: Amwell Appoints Mark Hirschhorn as New CFO, Succeeding Robert Shepardson

Amwell has announced the appointment of Mark Hirschhorn as its new Chief Financial Officer, effective October 21, 2024, following the resignation of Robert Shepardson.

Summary

• American Well Corporation (Amwell) has appointed Mark Hirschhorn as its new Chief Financial Officer (CFO), effective October 21, 2024.
• The previous CFO, Robert Shepardson, resigned on October 18, 2024, with no disagreements cited regarding company operations, policies, or practices.
• Mark Hirschhorn brings over three decades of experience in financial and strategic operations within the healthcare technology industry.
• Hirschhorn's previous roles include CEO of TapestryHealth, CFO and COO at Teladoc Health, and President and COO at Talkspace.
• Hirschhorn's compensation includes an annual base salary of $485,000, a 100% target bonus, a $500,000 bonus for fiscal year 2024, and significant equity grants.
• He will receive $2,500,000 in restricted stock units, with 25% vesting immediately and the remainder vesting over three years.
• Additionally, he is eligible for a $5,000,000 long-term incentive award based on EBITDA and company valuation targets, vesting over four years.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the appointment of an experienced CFO and a strategic shift towards profitability. However, the resignation of the previous CFO and the challenges of transitioning to an operational focus temper the overall sentiment.

Positives

• Mark Hirschhorn brings extensive experience in healthcare technology and financial operations.
• Hirschhorn has a proven track record of scaling revenue and profitability at previous companies.
• The new CFO appointment is part of Amwell's strategic shift towards operational efficiency and profitable growth.
• The compensation package for the new CFO includes significant incentives tied to company performance.

Negatives

• The resignation of the previous CFO, Robert Shepardson, may create a period of transition.
• The company is undergoing a shift from R&D investment to operational focus, which may present challenges.

Risks

• The company's ability to achieve the EBITDA and valuation targets required for the long-term incentive award is uncertain.
• The transition to a new CFO could potentially disrupt financial operations.
• The company's shift in focus from R&D to operational efficiency may impact innovation.

Future Outlook

Amwell aims to achieve greater efficiencies, optimize cash flow, and deliver profitable growth while maintaining its dedication to enabling clients' aspirations with the new CFO.

Management Comments

• Ido Schoenberg, M.D., chairman and CEO of Amwell, stated that Mark Hirschhorn's experience blends keen financial acumen and seasoned leadership.
• Schoenberg noted that this change represents an evolution for the company as it moves beyond a period of intense R&D investment to an operational focus.
• Mark Hirschhorn expressed excitement to join Amwell and stated his alignment with the leadership team's philosophies and strategies to build the business and enhance shareholder value.
• Schoenberg thanked Robert Shepardson for his contributions as CFO, noting his leadership during the IPO and re-platforming.

Industry Context

The appointment of a seasoned executive like Mark Hirschhorn, with experience at Teladoc and Talkspace, indicates a strategic move by Amwell to strengthen its financial position and operational efficiency in the competitive telehealth market.

Comparison to Industry Standards

• Mark Hirschhorn's previous roles at Teladoc Health and Talkspace provide a direct comparison to industry leaders in the telehealth space.
• His experience as CFO and COO at Teladoc, a major player in the telehealth industry, suggests that Amwell is aiming to emulate Teladoc's growth and operational strategies.
• The compensation package, including a base salary, bonus, and equity grants, is consistent with executive compensation practices in the healthcare technology sector.
• The long-term incentive award tied to EBITDA and company valuation targets is a common practice to align executive interests with shareholder value creation.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced CFO positively, potentially leading to increased confidence in the company's financial management.
• Employees may experience changes in the company's operational focus and financial strategies.
• Customers may benefit from the company's increased focus on efficiency and profitability, potentially leading to improved services.
• Suppliers and creditors may see the company as a more stable and reliable partner due to the strengthened financial leadership.

Next Steps

• Mark Hirschhorn will assume his role as CFO on October 21, 2024.
• Hirschhorn will receive his equity grants on or around November 4, 2024.
• The company will focus on achieving greater efficiencies, optimizing cash flow, and delivering profitable growth.

Key Dates

Keywords

CFO, Chief Financial Officer, Mark Hirschhorn, Robert Shepardson, executive appointment, healthcare technology, financial operations, equity incentives, EBITDA, company valuation, compensation, severance, restricted stock units, long-term incentive award, telehealth